Brought to you by 
Summit receives Japanese rights to Neuralstem’s neurogenic compound NSI189
25 Oct 2021
Executive Summary
Neuralstem Inc. (commercial production of brain and spinal cord stem cells) has licensed Summit Pharmaceuticals International Corp., the pharmaceutical R&D and services division of diversified company Sumitomo Corp., exclusive Japanese rights to develop and sell its NSI189, a Phase Ia compound for major depression that targets hippocampal neurogenesis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Summit receives Japanese rights to Neuralstem’s neurogenic compound NSI189
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice